CG Oncology (CGON) EBITDA (2023 - 2026)
CG Oncology (CGON) posted EBITDA of -$66.4 million for Q1 2026, down 36.32% on a QoQ basis from -$48.7 million in Q4 2025, and down 57.3% year-over-year from -$155.5 million in Q1 2025.
CG Oncology (CGON) EBITDA (2023 - 2026) Analysis & Trends
CG Oncology's EBITDA history runs 4 years deep, the most recent figure standing at -$66.4 million for Q1 2026.
- Quarterly EBITDA fell 57.3% year-over-year to -$66.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$215.0 million (down 59.94% YoY) and the FY2025 annual result came in at -$190.8 million, down 66.37% from the prior year.
- EBITDA was -$66.4 million for Q1 2026 at CG Oncology, down from -$48.7 million in the prior quarter.
- Across five years, EBITDA topped out at -$9.7 million in Q1 2023 and bottomed at -$66.4 million in Q1 2026.
- A 4-year average of -$32.9 million and a median of -$28.3 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA slumped 131.14% — and 2025, when it retreated 27.99%.
- CG Oncology's EBITDA stood at -$19.4 million in 2023, then slumped by 96.58% to -$38.0 million in 2024, then fell by 27.99% to -$48.7 million in 2025, then sank by 36.32% to -$66.4 million in 2026.
- Business Quant data shows CGON's EBITDA at -$66.4 million in Q1 2026, -$48.7 million in Q4 2025, and -$51.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | CG Oncology | 5.86 Bn | 5.86 Bn | -1.88 Mn | -66.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.39 Mn |
| Dec 31, 2025 | -48.70 Mn |
| Sep 30, 2025 | -51.13 Mn |
| Jun 30, 2025 | -48.74 Mn |
| Mar 31, 2025 | -42.20 Mn |
| Dec 31, 2024 | -38.05 Mn |
| Sep 30, 2024 | -28.30 Mn |
| Jun 30, 2024 | -25.85 Mn |
| Mar 31, 2024 | -22.47 Mn |
| Dec 31, 2023 | -19.36 Mn |
| Sep 30, 2023 | -14.04 Mn |
| Jun 30, 2023 | -12.33 Mn |
| Mar 31, 2023 | -9.72 Mn |